Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PFE

Follow the Footprints: 3 Stocks with Unusual Options Activity That You Can’t Ignore

On a day when nothing worked for investors, yesterday’s unusual options activity had plenty of variety, especially in the top three. Here’s how investors might have played each of the stock's and their options.

Barchart

Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.

As oil prices rise with increasing global uncertainty, this pharmaceutical stock emerges as a possible safe haven for income investors.

Barchart

EU Parliament firewall breached? EPP reportedly worked closely with AfD

Investigations suggest the EPP group in the European Parliament cooperated more closely with right-wing parties, including the AfD, on tougher EU migration laws, with a chat group and a meeting of MEPs playing a key role.

Euronews

From analysis to the latest developments in health,
read the most diverse news in one place.

The Best Covered Call Strategy to Trade High-Yielding Pfizer Stock and Earn Extra Income

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start. Pfizer (PFE) has been a strong performer in 2026 and is up 9.64% so far this year.

Barchart

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

Barchart

Exclusive: European Parliament rejects minute of silence for killed French far-right activist

The death of Quentin Deranque has provoked intense political reactions in France and abroad, only weeks before local elections in which both the far left and the far right are expected to make substantial gains.

Euronews

Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

MarketBeat

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Barchart

What Are Wall Street Analysts' Target Price for Pfizer Stock?

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Barchart

Pfizer's Quarterly Earnings Preview: What You Need to Know

Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

Barchart

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

MarketBeat

Best of 2025: Top five defining moments in the European Parliament

New alliances, multiple attempts to topple the European Commission boss and yet another investigation into corruption marked the European Parliament's year. Here are the top moments of 2025 selected by Euronews.

Euronews

MarketBeat Week in Review – 12/15 - 12/19

Money continues to move into the market, raising hopes for a Santa Claus rally; however, the macro story remains mixed, which could bring more volatility

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Stocks Chop as the Unemployment Rate Jumps: Stock Market Today

November job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.

Barchart

Covered Call Screener Results For Dec 10th

Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.

Euronews

How the EPP ushered in a right-wing majority at the European Parliament

For the first time, a right-wing majority is emerging at the European Parliament as the European People's Party flirts with groups that would have been considered too toxic to work with in the past. The pivot has given the EPP a choice but also created a headache for Ursula von…

Euronews

EPP teams up with far right to water down reporting requirements for companies

The European Parliament approved a package to ease corporate sustainability reporting and due diligence requirements. EPP teamed up with conservative and far-right MEPs to pass the law.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter 2025 adjusted earnings of 87 cents, compared to $1.06 a year ago, beating the consensus of 63 cents.

Barchart

Pfizer Stock: Is Wall Street Bullish or Bearish?

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Benzinga

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.

MarketBeat

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

MarketBeat

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

Euronews

Votes of confidence: Which political groups will defend von der Leyen?

The European Commission is set to survive the two motions of censure to be voted on Thursday. But its support could shrink even more.

MarketBeat

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.